Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EBIT (2020 - 2025)

Historic EBIT for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$4.7 million.

  • Vivos Therapeutics' EBIT fell 7897.92% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.3 million, marking a year-over-year decrease of 3059.44%. This contributed to the annual value of -$11.2 million for FY2024, which is 3541.28% up from last year.
  • According to the latest figures from Q3 2025, Vivos Therapeutics' EBIT is -$4.7 million, which was down 7897.92% from -$4.9 million recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' EBIT registered a high of -$1.9 million during Q2 2024, and its lowest value of -$7.4 million during Q4 2021.
  • For the 5-year period, Vivos Therapeutics' EBIT averaged around -$4.6 million, with its median value being -$4.5 million (2023).
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 20282.6% in 2021, then surged by 5713.97% in 2024.
  • Over the past 5 years, Vivos Therapeutics' EBIT (Quarter) stood at -$7.4 million in 2021, then increased by 18.19% to -$6.1 million in 2022, then soared by 31.83% to -$4.1 million in 2023, then surged by 32.11% to -$2.8 million in 2024, then tumbled by 68.71% to -$4.7 million in 2025.
  • Its EBIT stands at -$4.7 million for Q3 2025, versus -$4.9 million for Q2 2025 and -$3.9 million for Q1 2025.